{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T19:54:52Z","timestamp":1792958092892,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Japan Society for the Promorion of Science","award":["25461404"],"award-info":[{"award-number":["25461404"]}]},{"name":"North Japan Hematology Study Group"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s12185-019-02696-w","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T16:25:18Z","timestamp":1561479918000},"page":"482-489","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical efficacy and safety of first-line nilotinib therapy and evaluation of the clinical utility of the FRET-based drug sensitivity test"],"prefix":"10.1007","volume":"110","author":[{"name":"The North Japan Hematology Study Group (NJHSG)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7455-5824","authenticated-orcid":false,"given":"Takeshi","family":"Kondo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masumi","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Miyagishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Kakinoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Haseyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seisho","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Shindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutoshi","family":"Kurosawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ohba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,25]]},"reference":[{"key":"2696_CR1","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","volume":"112","author":"BJ Druker","year":"2008","unstructured":"Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008;112:4808\u201317.","journal-title":"Blood"},{"key":"2696_CR2","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Investigators IRIS, et al. Long-Term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med"},{"key":"2696_CR3","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531\u201341.","journal-title":"N Engl J Med"},{"key":"2696_CR4","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, Bhalla K, O\u2019Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542\u201351.","journal-title":"N Engl J Med"},{"key":"2696_CR5","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251\u20139.","journal-title":"N Engl J Med"},{"key":"2696_CR6","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260\u201370.","journal-title":"N Engl J Med"},{"key":"2696_CR7","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12:841\u201351.","journal-title":"Lancet Oncol"},{"key":"2696_CR8","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","volume":"120","author":"JP Radich","year":"2012","unstructured":"Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, et al. A randomized trial of dasatinib 100\u00a0mg vs imatinib 400\u00a0mg in newly diagnosed chronic phase chromic myeloid leukemia. Blood. 2012;120:3898\u2013905.","journal-title":"Blood"},{"key":"2696_CR9","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333\u201340.","journal-title":"J Clin Oncol"},{"key":"2696_CR10","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044\u201354.","journal-title":"Leukemia"},{"key":"2696_CR11","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood"},{"key":"2696_CR12","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajh.25342","volume":"94","author":"J Cortes","year":"2019","unstructured":"Cortes J, Rea D, Lipton JH. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. Am J Hematol. 2019;94:346\u201357.","journal-title":"Am J Hematol"},{"key":"2696_CR13","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/j.clml.2016.03.003","volume":"16","author":"S Yun","year":"2016","unstructured":"Yun S, Vincelette ND, Segar JM, Dong Y, Shen Y, Kim DW, et al. Comparative effectiveness of newer tyrosine kinase inhibitors versus imatinib in the first-line treatment of chronic-phase chronic myeloid leukemia across risk groups: a systematic review and meta-analysis of eight randomized trials. Clin Lymphoma Myeloma Leuk. 2016;16:e85\u201394.","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"2696_CR14","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","volume":"116","author":"TP Hughes","year":"2010","unstructured":"Hughes TP, Hochhaus A, Branford S, M\u00fcller MC, Kaeda JS, Foroni L, et al. IRIS investigators. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116:3758\u201365.","journal-title":"Blood"},{"key":"2696_CR15","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, et al. Assessment of BCR-ABL1 transcript levels at 3\u00a0months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30:232\u20138.","journal-title":"J Clin Oncol"},{"key":"2696_CR16","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B, M\u00fcller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, SAKK; German CML Study Group, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012;26:2096\u2013102.","journal-title":"Leukemia"},{"key":"2696_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2012-01-407486","volume":"120","author":"D Marin","year":"2012","unstructured":"Marin D, Hedgley C, Clark RE, Apperley J, Foroni L, Milojkovic D, et al. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood. 2012;120:291\u20134.","journal-title":"Blood"},{"key":"2696_CR18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","volume":"124","author":"S Branford","year":"2014","unstructured":"Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA, et al. Prognosis for patients with CML and >\u200910% BCR-ABL1 after 3\u00a0months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 2014;124:511\u20138.","journal-title":"Blood"},{"key":"2696_CR19","doi-asserted-by":"publisher","first-page":"e106250","DOI":"10.1371\/journal.pone.0106250","volume":"9","author":"S Huet","year":"2014","unstructured":"Huet S, Cony-Makhoul P, Heiblig M, Tigaud I, Gazzo S, Belhabri A, et al. Major molecular response achievement in CML Patients can be predicted by BCR-ABL1\/ABL1 or BCR-ABL1\/GUS ratio at an earlier time point of follow-up than currently recommended. PLOS One. 2014;9:e106250.","journal-title":"PLOS One."},{"key":"2696_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41408-018-0093-4","volume":"8","author":"J Zhang","year":"2018","unstructured":"Zhang J, Wang Y, Wang J, Hu J, Chen S, Jin J, et al. Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance. Blood Cancer J. 2018;8:61.","journal-title":"Blood Cancer J."},{"key":"2696_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ejh.12969","volume":"100","author":"K Murai","year":"2018","unstructured":"Murai K, Yamaguchi K, Ito S, Miyagishima T, Shindo M, Wakasa K, et al. Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patients. Eur J Haematol. 2018;100:27\u201335.","journal-title":"Eur J Haematol"},{"key":"2696_CR22","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ajh.23923","volume":"90","author":"N Iriyama","year":"2015","unstructured":"Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, et al. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-first study of Kanto CML study group. Am J Hematol. 2015;90:282\u20137.","journal-title":"Am J Hematol"},{"key":"2696_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000481945","volume":"94","author":"T Takaku","year":"2018","unstructured":"Takaku T, Iriyama N, Mitsumori T, Sato E, Gotoh A, Kirito K, et al. Clinical efficacy and safety of first-line dasatinib therapy and the relevance of velocity of BCR-ABL1 transcript decline for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia: report from the Juntendo Yamanashi Cooperative Study Group. Oncology. 2018;94:85\u201391.","journal-title":"Oncology"},{"key":"2696_CR24","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s00432-017-2445-z","volume":"143","author":"JL Steegmann","year":"2017","unstructured":"Steegmann JL, Colomer D, G\u00f3mez-Casares MT, Garc\u00eda-Guti\u00e9rrez V, Ort\u00ed G, Ram\u00edrez-Payer A, et al. An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol. 2017;143:2059\u201366.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2696_CR25","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1158\/1078-0432.CCR-10-0548","volume":"16","author":"T Mizutani","year":"2010","unstructured":"Mizutani T, Kondo T, Darmanin S, Tsuda M, Tanaka S, Tobiume M, et al. A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells. Clin Cancer Res. 2010;16:3964\u201375.","journal-title":"Clin Cancer Res"},{"key":"2696_CR26","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1111\/cas.13625","volume":"109","author":"T Kondo","year":"2018","unstructured":"Kondo T, Fujioka M, Tsuda M, Murai K, Yamaguchi K, Miyagishima T, Inter-Michinoku Dasatinib Study Group (IMIDAS), et al. Pretreatment evaluation of fluorescence resonance energy transfer-based drug sensitivity test for patients with chronic myelogenous leukemia treated with dasatinib. Cancer Sci. 2018;109:2256\u201365.","journal-title":"Cancer Sci."},{"key":"2696_CR27","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s12185-011-0841-8","volume":"93","author":"H Nakamae","year":"2011","unstructured":"Nakamae H, Shibayama H, Kurokawa M, Fukuda T, Nakaseko C, Kanda Y, et al. Nilotinib\u00a0as frontline therapy for patients with newly diagnosed Ph\u2009+\u2009chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd. Int J Hematol. 2011;93:624\u201332.","journal-title":"Int J Hematol"},{"key":"2696_CR28","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s12185-017-2353-7","volume":"107","author":"H Nakamae","year":"2018","unstructured":"Nakamae H, Fukuda T, Nakaseko C, Kanda Y, Ohmine K, Ono T, et al. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial. Int J Hematol. 2018;107:327\u201336.","journal-title":"Int J Hematol."},{"key":"2696_CR29","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s10147-011-0328-x","volume":"17","author":"C Yoshida","year":"2012","unstructured":"Yoshida C, Fletcher L, Ohashi K, Wakita H, Kumagai T, Shiseki M, et al. Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan. Int J Clin Oncol. 2012;17:584\u20139.","journal-title":"Int J Clin Oncol."},{"key":"2696_CR30","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1365-2141.2010.08245.x","volume":"150","author":"FP Santos","year":"2010","unstructured":"Santos FP, Kantarjian H, Fava C, O\u2019Brien S, Garcia-Manero G, Ravandi F, et al. Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol. 2010;150:303\u201312.","journal-title":"Br J Haematol"},{"key":"2696_CR31","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s12032-018-1093-8","volume":"35","author":"M Tokuhira","year":"2018","unstructured":"Tokuhira M, Kimura Y, Sugimoto K, Nakazato T, Ishikawa M, Fujioka I, et al. Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase. Med Oncol. 2018;35:38.","journal-title":"Med Oncol."},{"key":"2696_CR32","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/bjh.14829","volume":"179","author":"TP Hughes","year":"2017","unstructured":"Hughes TP, Munhoz E, Aurelio Salvino M, Ong TC, Elhaddad A, Shortt J, et al. Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd. Br J Haematol. 2017;179:219\u201328.","journal-title":"Br J Haematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02696-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-019-02696-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02696-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T19:07:09Z","timestamp":1694977629000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-019-02696-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,25]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["2696"],"URL":"https:\/\/doi.org\/10.1007\/s12185-019-02696-w","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,25]]},"assertion":[{"value":"23 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"TK has received honoraria from Bristol-Myers Squibb, Novartis, and Ohtsuka Pharmaceutical, a grant from Bristol-Myers Squibb, and research funding from Novartis. SO has received honoraria from Novartis. YO has received honoraria from Novartis and Lonza, a grant from Bristol-Myers Squibb, and research funding from Ohtsuka Pharmaceutical. TT has received honoraria and grants from Bristol-Myers Squibb, Novartis, and Ohtsuka Pharmaceutical. The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}